留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

无偿献血者隐匿性HBV感染机制和检测研究进展

刘旆 张伯语 李薇 段友斌

刘旆, 张伯语, 李薇, 段友斌. 无偿献血者隐匿性HBV感染机制和检测研究进展[J]. 昆明医科大学学报.
引用本文: 刘旆, 张伯语, 李薇, 段友斌. 无偿献血者隐匿性HBV感染机制和检测研究进展[J]. 昆明医科大学学报.
Pei LIU, Boyu ZHANG, Wei LI, Youbin DUAN. Infection Mechanism and Detection of Occult Hepatitis B Virus in Voluntary Blood Donors[J]. Journal of Kunming Medical University.
Citation: Pei LIU, Boyu ZHANG, Wei LI, Youbin DUAN. Infection Mechanism and Detection of Occult Hepatitis B Virus in Voluntary Blood Donors[J]. Journal of Kunming Medical University.

无偿献血者隐匿性HBV感染机制和检测研究进展

基金项目: 国家自然科学基金(82460114);云南省科技厅基础研究计划昆医联合专项-面上项目(202501AY07001-250;202401AY070001-248)
详细信息
    作者简介:

    刘旆(1994~),女,云南昆明人,医学学士,输血师,主要从事采供血工作

    通讯作者:

    李薇,E-mail:770583965@qq.com

    段友斌,E-mail:binfox2@163.com

  • 中图分类号: R512.6

Infection Mechanism and Detection of Occult Hepatitis B Virus in Voluntary Blood Donors

  • 摘要: 发生输血后肝炎(post transfusion hepatitis,PTH)的风险主要来自于输入HBsAg阴性的HBV感染血液,即血清学窗口期(window period,WP)和隐匿性HBV感染(occult HBV infection,OBI)。其中,OBI是一种低病毒复制的HBV,因此成为了乙肝病毒感染防治的难点,也是输血后肝炎的重要传染源之一。虽然通过核酸检测技术(nucleic acid test,NAT)能一定程度上减少输血后肝炎发生,但有部分OBI感染者在献血者中存在,是HBV经血传播的潜在风险。本文主要对OBI的概念、血清学特征、基因组特征、发生机制、流行病学特点和检测策略进展进行概述。
  • 图  1  宿主细胞与乙肝病毒相互作用机制示意图(用BioRender网站自制)

    Figure  1.  Schematic diagram of the interaction mechanism between host cells and hepatitis B virus(Created in BioRender.com)

    表  1  不同NAT检测技术性能对比

    Table  1.   Performance comparison of different NAT detection technologies

    维度灵敏度检测速度检测优势成本效益血液筛查
    TMA快(等温)RNA病毒较高单样本检测
    PCR受限于试剂较慢(热循环)DNA病毒,RNA需逆转录适合常规筛查混样检测
    下载: 导出CSV
  • [1] Raimondo G, Pollicino T, Cacciola I, et al. Occult hepatitis B virus infection[J]. J Hepatol, 2007, 46(1): 160-170. doi: 10.1016/j.jhep.2006.10.007
    [2] Cacciola I, Pollicino T, Squadrito G, et al. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease[J]. N Engl J Med, 1999, 341(1): 22-26. doi: 10.1056/NEJM199907013410104
    [3] 尤红, 王福生, 李太生, 等. 慢性乙型肝炎防治指南(2022年版)[J]. 实用肝脏病杂志, 2023, 26(3): 457-478.
    [4] Wei L, Chen M, Wang F, et al. Analysis of hepatitis B virus test results among blood donors in Chongqing, China[J]. BMC Infect Dis, 2024, 24(1): 857. doi: 10.1186/s12879-024-09753-8
    [5] 胡一钦, 黄纪红, 王敏, 等. 血液核酸筛查系统在不同检测筛查模式下的乙肝检测结果分析及评价[J]. 中国输血杂志, 2024, 37(9): 1030-1035.
    [6] Raimondo G, Locarnini S, Pollicino T, et al. Update of the statements on biology and clinical impact of occult hepatitis B virus infection[J]. J Hepatol, 2019, 71(2): 397-408. doi: 10.1016/j.jhep.2019.03.034
    [7] Song S H, Hwang S G. Occult hepatitis B virus infection: transmission and reactivation[J]. Korean J Gastroenterol, 2013, 62(3): 148-153. doi: 10.4166/kjg.2013.62.3.148
    [8] Saitta C, Pollicino T, Raimondo G. Occult hepatitis B virus Infection: An update[J]. Viruses, 2022, 14(7): 1504. doi: 10.3390/v14071504
    [9] Vaillant A. HBsAg, Subviral particles, and their clearance in establishing a functional cure of chronic hepatitis B virus Infection[J]. ACS Infect Dis, 2021, 7(6): 1351-1368. doi: 10.1021/acsinfecdis.0c00638
    [10] Fu M X, Faddy H M, Candotti D, et al. International review of blood donation screening for anti-HBc and occult hepatitis B virus infection[J]. Transfusion, 2024, 64(11): 2144-2156. doi: 10.1111/trf.18018
    [11] Deng X, Guo X, Gu H, et al. Anti-HBc-nonreactive occult hepatitis B infections with HBV genotypes B and C in vaccinated immunocompetent adults[J]. J Viral Hepat, 2022, 29(11): 958-967. doi: 10.1111/jvh.13733
    [12] Pisaturo M, Onorato L, Russo A, et al. An estimation of the prevalence of occult HBV infection in Western Europe and in Northern America: A meta-analysis[J]. J Viral Hepat, 2020, 27(4): 415-427. doi: 10.1111/jvh.13248
    [13] 刘佳惠, 王贝, 周丽玲. 徐州地区献血者人群隐匿性乙型肝炎病毒感染现状及血清学特征分析[J]. 中国输血杂志, 2025, 38(3): 402-407.
    [14] Herrscher C, Roingeard P, Blanchard E. Hepatitis B virus entry into cells[J]. Cells, 2020, 9(6): 1486. doi: 10.3390/cells9061486
    [15] Sun H, Chang L, Yan Y, et al. Hepatitis B virus pre-S region: clinical implications and applications [J]. Rev Med Virol, 2020. Epub ahead of print.
    [16] Thi Cam Huong N, Trung N Q, Luong B A, et al. Mutations in the HBV PreS/S gene related to hepatocellular carcinoma in Vietnamese chronic HBV-infected patients[J]. PLoS One, 2022, 17(4): e0266134. doi: 10.1371/journal.pone.0266134
    [17] Cakal B, Cavus B, Atasoy A, et al. Comparison of S gene mutations in patients with occult and chronic hepatitis B virus infection[J]. Virus Res, 2022, 318: 198855. doi: 10.1016/j.virusres.2022.198855
    [18] Kitab B, El Feydi A E, Afifi R, et al. Hepatitis B genotypes/subgenotypes and MHR variants among Moroccan chronic carriers[J]. J Infect, 2011, 63(1): 66-75. doi: 10.1016/j.jinf.2011.05.007
    [19] Liu X, Chen S X, Liu H, et al. Host immunity and HBV S gene mutation in HBsAg-negative HBV-infected patients[J]. Front Immunol, 2023, 14: 1211980. doi: 10.3389/fimmu.2023.1211980
    [20] Kumar R. Review on hepatitis B virus precore/core promoter mutations and their correlation with genotypes and liver disease severity[J]. World J Hepatol, 2022, 14(4): 708-718. doi: 10.4254/wjh.v14.i4.708
    [21] Yu Y, Kass M A, Zhang M, et al. Deep mutational scanning of hepatitis B virus reveals a mechanism for cis-preferential reverse transcription [J]. Cell, 2024, 187(11): 2735-2745. e12.
    [22] Fernandes Da Silva C, Keeshan A, Cooper C. Hepatitis B virus genotypes influence clinical outcomes: A review[J]. Can Liver J, 2023, 6(3): 347-352. doi: 10.3138/canlivj-2023-0003
    [23] Sekiba K, Miyake N, Miyakawa Y, et al. CRISPR-mediated proximity labeling unveils ABHD14B as a host factor to regulate HBV cccDNA transcriptional activity[J]. Hepatol Commun, 2025, 9(8): e0757.
    [24] Vyas A K, Banu S A, Rahangdale K, et al. Dissection the hepatitis B virus replication mechanisms and advances in In Vivo models: A comprehensive review [J]. Dig Dis, 2025: 1-31.
    [25] Venkatesan H, Mahesh J S, Venkataraman S. Decoding hepatitis B virus mutations that impact host-virus interactions and therapeutics [J]. J Biosci, 2025, 50.
    [26] Zhang J, Lou T, Zhu M, et al. Virus-host interaction mechanisms in interferon therapy for hepatitis B virus infection: Recent advances[J]. Front Immunol, 2025, 16: 1603544. doi: 10.3389/fimmu.2025.1603544
    [27] Kostyusheva A, Brezgin S, Glebe D, et al. Host-cell interactions in HBV infection and pathogenesis: The emerging role of m6A modification[J]. Emerg Microbes Infect, 2021, 10(1): 2264-2275. doi: 10.1080/22221751.2021.2006580
    [28] Salih A, Inoue S, Onwuzurike N. Rothmund-Thomson syndrome (RTS) with osteosarcoma due to RECQL4 mutation[J]. BMJ Case Rep, 2018, 2018: bcr2017222384. doi: 10.1136/bcr-2017-222384
    [29] Lu L, Jin W, Wang L L. Aging in Rothmund-Thomson syndrome and related RECQL4 genetic disorders[J]. Ageing Res Rev, 2017, 33: 30-35. doi: 10.1016/j.arr.2016.06.002
    [30] Lelie N, Bruhn R, Busch M, et al. Detection of different categories of hepatitis B virus (HBV) infection in a multi-regional study comparing the clinical sensitivity of hepatitis B surface antigen and HBV-DNA testing[J]. Transfusion, 2017, 57(1): 24-35. doi: 10.1111/trf.13819
    [31] Candotti D, Lin C K, Belkhiri D, et al. Occult hepatitis B infection in blood donors from South East Asia: molecular characterisation and potential mechanisms of occurrence[J]. Gut, 2012, 61(12): 1744-1753. doi: 10.1136/gutjnl-2011-301281
    [32] 范加诚, 李青, 陈秀丽, 等. 献血者HBVs基因变异的生物信息学分析[J]. 中国输血杂志, 2024, 37(8): 933-939.
    [33] 晁春梅, 哏传香, 金正英, 等. 2015-2019年云南省献血者血清阳性隐匿性乙肝病毒感染流行病学特征[J]. 热带医学杂志, 2021, 21(5): 650-652+669.
    [34] 叶贤林, 李彤, 王若楠, 等. 计划免疫后出生献血者乙肝无症状慢性感染血清学与分子生物学特征分析[J]. 中国输血杂志, 2024, 37(1): 26-31.
    [35] Mak L Y, Wong D K, Pollicino T, et al. Occult hepatitis B infection and hepatocellular carcinoma: Epidemiology, virology, hepatocarcinogenesis and clinical significance[J]. J Hepatol, 2020, 73(4): 952-964. doi: 10.1016/j.jhep.2020.05.042
    [36] 吴诗阳, 孙加进, 杨州. 乙肝血清学检测研究进展[J]. 现代医学与健康研究电子杂志, 2023, 7(23): 134-137.
    [37] Lalana Garcés M, Ortiz Pastor O, Solé Enrech G, et al. Control of occult hepatitis B virus infection[J]. Adv Lab Med, 2022, 3(4): 321-341.
    [38] 王全慧, 潘彤, 樊晶. 隐匿性乙型肝炎病毒感染的输血传播风险及防范[J]. 检验医学与临床, 2024, 21(6): 838-841+861.
    [39] Pathak A, Panda D, Sharma M, et al. Blood donation Screening of transfusion-transmissible viral infection using two different nucleic acid testing (NAT) platforms: A single tertiary care oncology centre experience[J]. Indian J Hematol Blood Transfus, 2023, 39(3): 456-463. doi: 10.1007/s12288-022-01598-y
    [40] Manso T, De Salazar A, Rodríguez-Velasco M, et al. Detection and quantification of HBV and HCV in plasma samples by means of different molecular assays: comparative study[J]. Enferm Infecc Microbiol Clin (Engl Ed), 2024, 42(1): 13-16. doi: 10.1016/j.eimc.2022.07.007
    [41] Wu D, Feng F, Wang X, et al. The impact of nucleic acid testing to detect human immunodeficiency virus, hepatitis C virus, and hepatitis B virus yields from a single blood center in China with 10-years review[J]. BMC Infect Dis, 2022, 22(1): 279. doi: 10.1186/s12879-022-07279-5
    [42] Abbasian S, Sharifi Z, Maghsudlu M. Prevalence of Hepatitis b virus infection among voluntary blood donors from the northeastern region of Iran: Genotyping, viral load characterization and drug resistance prediction[J]. Clin Lab, 2021, 67(1): 10.7754.
    [43] D'souza S, Al-Yasiri L, Chen A, et al. Development of low-cost in-house assays for quantitative detection of HBsAg, HBeAg, and HBV DNA to enhance hepatitis B virus diagnostics and antiviral screening in resource-limited settings[J]. Pathogens, 2025, 14(3): 258. doi: 10.3390/pathogens14030258
    [44] Bermúdez-Forero M I, García-Otálora M A. Nucleic acid testing in Colombian blood banks (2018-2024): Implementation, yield estimates and implications for safer transfusion policy [J]. Vox Sang, 2025, Epub ahead of print.
    [45] Liu Y, Ma Y. Clinical applications of metagenomics next-generation sequencing in infectious diseases[J]. J Zhejiang Univ Sci B, 2024, 25(6): 471-484. doi: 10.1631/jzus.B2300029
    [46] Qi H, Lv J, Liao J, et al. Metagenomic insights into microalgae-bacterium-virus interactions and viral functions in phycosphere facing environmental fluctuations [J]. Water Res, 2025, 268(Pt A): 122676.
    [47] Slavov S N. Viral metagenomics for identification of emerging viruses in transfusion medicine[J]. Viruses, 2022, 14(11): 2448. doi: 10.3390/v14112448
    [48] Rodino K G, Simner P J. Status check: next-generation sequencing for infectious-disease diagnostics[J]. J Clin Invest, 2024, 134(4): e178003. doi: 10.1172/JCI178003
    [49] Schlaberg R, Chiu C Y, Miller S, et al. Validation of metagenomic next-generation sequencing tests for universal pathogen detection[J]. Arch Pathol Lab Med, 2017, 141(6): 776-786. doi: 10.5858/arpa.2016-0539-RA
    [50] Simner P J, Miller S, Carroll K C. Understanding the promises and hurdles of metagenomic next-generation sequencing as a diagnostic tool for infectious diseases[J]. Clin Infect Dis, 2018, 66(5): 778-788. doi: 10.1093/cid/cix881
    [51] Guzman-Cole C, Huang A D. Nf-UnO-pipeline: A nextflow metagenomic co-assembly pipeline for novel pathogen detection of mNGS outbreak sets[J]. Bioinformatics, 2025, 41(8): btaf436. doi: 10.1093/bioinformatics/btaf436
    [52] 赖伟兰, 谢丽明, 陈亚军. 基于高通量测序下低拷贝乙型肝炎病毒检测方法的应用分析[J]. 国际检验医学杂志, 2018, 39(23): 2937-2940.
    [53] Berg M G, Olivo A, Forberg K, et al. Advanced molecular surveillance approaches for characterization of blood borne hepatitis viruses[J]. PLoS One, 2020, 15(7): e0236046. doi: 10.1371/journal.pone.0236046
    [54] Zhang Y, Sun D, Fang Y, Et al. Uncommon pulmonary manifestation of hepatitis B virus: A case report of secondary organizing pneumonia[J]. BMC Infect Dis, 2025, 25(1): 645. doi: 10.1186/s12879-025-11049-4
    [55] Gao D Q, Hu Y Q, Wang X, et al. Hepatitis B virus in cerebrospinal fluid of a patient with purulent bacterial meningitis detected by multiplex-PCR: A case report[J]. World J Clin Cases, 2022, 10(5): 1697-1701. doi: 10.12998/wjcc.v10.i5.1697
    [56] Stramer S L. Current perspectives in transfusion-transmitted infectious diseases: Emerging and re-emerging infections[J]. ISBT Sci Ser, 2014, 9(1): 30-36. doi: 10.1111/voxs.12070
    [57] Mengyi Z, Yuhui L, Zhan G, et al. Plasma metagenomics reveals regional variations of emerging and re-emerging pathogens in Chinese blood donors with an emphasis on human parvovirus B19[J]. One Health, 2023, 17: 100602. doi: 10.1016/j.onehlt.2023.100602
    [58] Towner J S, Sealy T K, Khristova M L, et al. Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda[J]. PLoS Pathog, 2008, 4(11): e1000212. doi: 10.1371/journal.ppat.1000212
    [59] Mishra N, Pereira M, Rhodes R H, et al. Identification of a novel polyomavirus in a pancreatic transplant recipient with retinal blindness and vasculitic myopathy[J]. J Infect Dis, 2014, 210(10): 1595-1599. doi: 10.1093/infdis/jiu250
    [60] Zheng N, Yu H L, Zhang B J, et al. Metagenomic next-generation sequencing-based characterization of the viral spectrum in clinical pulmonary and peripheral blood samples of patients[J]. Front Cell Infect Microbiol, 2025, 15: 1562965. doi: 10.3389/fcimb.2025.1562965
  • [1] 艾骞, 赵智蓉, 吴月, 李海雯, 李生浩, 杨永锐.  不确定期慢性乙型肝炎病毒感染患者抗病毒疗效及安全性分析, 昆明医科大学学报. 2025, 46(1): 51-59. doi: 10.12259/j.issn.2095-610X.S20250107
    [2] 杨玉峰, 李世福, 周林慧, 赵金仙, 蔡英, 李顺祥, 陈黎跃.  玉溪市2010—2021年无偿献血及受血人群HIV感染情况及特征分析, 昆明医科大学学报. 2025, 46(9): 1-7.
    [3] 陈春燕, 樊子勉.  慢性乙型肝炎者外周血SAA/CRP、NLR水平与HBV-DNA载量、病情程度的相关性分析, 昆明医科大学学报. 2024, 45(5): 144-150. doi: 10.12259/j.issn.2095-610X.S20240522
    [4] 王学丹, 刘一帆, 杨子寒, 张丹丹, 段怡, 杨志惠.  阑尾黏液性肿瘤临床病理及分子病理特征分析, 昆明医科大学学报. 2024, 45(7): 42-48. doi: 10.12259/j.issn.2095-610X.S20240706
    [5] 武媞, 黄康, 赵智蓉, 李海雯, 李晓非, 杨永锐.  ALT升高、低病毒载量慢性乙型肝炎患者不确定期采用不同抗病毒治疗方案的疗效及安全性, 昆明医科大学学报. 2023, 44(1): 97-103. doi: 10.12259/j.issn.2095-610X.S20230117
    [6] 何建萍, 吕梦欣, 秦茂华, 朱丽虹, 党峰博, 孙永波, 罗胜军, 罗兰, 唐健.  昆明地区357例Gilbert综合征基因变异谱分析, 昆明医科大学学报. 2023, 44(10): 155-160. doi: 10.12259/j.issn.2095-610X.S20231015
    [7] 刘秋燕, 熊伟, 李程.  鼻咽癌同期放化疗抵抗细胞株与母细胞株lncRNA的差异表达谱分析, 昆明医科大学学报. 2022, 43(11): 77-84. doi: 10.12259/j.issn.2095-610X.S20221108
    [8] 李馨怡, 李玥晓, 李黎仙, 李永平, 高鹰, 李艳红.  大学生牙龈炎龈上菌斑的微生物群落, 昆明医科大学学报. 2022, 43(2): 102-106. doi: 10.12259/j.issn.2095-610X.S20220207
    [9] 曹凡, 刘阳文, 魏雷, 谢楠, 杨裔坚, 钱程, 李春满, 付必莽, 胥江品, 阎容稷, 曾汪.  乙型肝炎病毒与肝细胞癌微血管侵犯的相关性, 昆明医科大学学报. 2021, 42(3): 127-134. doi: 10.12259/j.issn.2095-610X.S20210331
    [10] 徐应芳, 黄洁, 肖成, 李江, 李薇, 许广芳, 谭建玲.  全程输血质量管理在血液标本2次血型鉴定结果不一致中的应用研究, 昆明医科大学学报. 2021, 42(11): 148-152. doi: 10.12259/j.issn.2095-610X.S20211035
    [11] 谢巍, 赵川, 王容, 王文平, 涂宏.  慢性乙型肝炎患者外周血T淋巴细胞程序性死亡受体1表达与HBV-DNA水平的相关性, 昆明医科大学学报. 2020, 41(02): 82-86.
    [12] 罗伟, 王顺军, 方克伟, 陈韬, 陈蓉琼, 王辉涛, 杨博伟, 郭海翔, 张海燕, 李沛, 柯昌兴, 刘建和.  隐匿阴茎改良手术的疗效与安全性观察, 昆明医科大学学报. 2019, 40(12): 124-129.
    [13] 殷顺会, 詹烨明, 贾凤梅, 冉丽权, 张明珠.  高通量测序筛查特发性牙龈纤维瘤和正常牙龈外泌体miRNAs差异表达, 昆明医科大学学报. 2019, 40(04): 23-30.
    [14] 杨永锐, 李晓非, 刘俊, 郭映武, 沈凌.  38例隐匿性乙型肝炎抗病毒治疗的临床分析, 昆明医科大学学报. 2018, 39(11): 110-113.
    [15] 熊晶晶, 祁文瑾, 胡红卫, 曾洁, 黄蓉, 马润玫, 刘梅, 黄永坤.  正常足月儿母亲胎盘菌群检析, 昆明医科大学学报. 2017, 38(11): 52-57.
    [16] 李永刚.  乙型肝炎病毒在人类早期胚胎中的垂直传播, 昆明医科大学学报. 2016, 37(10): -.
    [17] 宁琳.  佩普洛人际关系理论对慢性乙型肝炎患者的护理效果, 昆明医科大学学报. 2015, 36(06): -1.
    [18] 蔡艳.  高通量透析对维持性血液透析患者钙磷代谢的影响, 昆明医科大学学报. 2014, 35(09): -1.
    [19] 苏莹.  慢性乙型肝炎患者外周血Th17细胞的变化及意义, 昆明医科大学学报. 2013, 34(07): -.
    [20] 张倩.  妊娠合并乙型肝炎患者乙肝五项定量与HBV-DNA结果相关性分析, 昆明医科大学学报. 2013, 34(03): -.
  • 加载中
图(1) / 表(1)
计量
  • 文章访问数:  11
  • HTML全文浏览量:  9
  • PDF下载量:  0
  • 被引次数: 0
出版历程
  • 收稿日期:  2025-05-15

目录

    /

    返回文章
    返回